摘要事件:公司发布2025年中期业绩,报告期内公司实现营业收入2.78亿美元,实现归母净利润4.55亿美元。呋喹替尼海外市场持续放量。海外市场上,由武田负责销售的FRUZAQLA® (呋喹替尼的海外商品名) 市场销售额增长25%至1.628亿美元,得益于覆盖范围扩大至超过30个国家。国内市场上,爱优特® (呋喹替尼的中国商品名) 实现销售额4,300万美元 (2024年上半年: 6,100万美元)...
Source Link摘要事件:公司发布2025年中期业绩,报告期内公司实现营业收入2.78亿美元,实现归母净利润4.55亿美元。呋喹替尼海外市场持续放量。海外市场上,由武田负责销售的FRUZAQLA® (呋喹替尼的海外商品名) 市场销售额增长25%至1.628亿美元,得益于覆盖范围扩大至超过30个国家。国内市场上,爱优特® (呋喹替尼的中国商品名) 实现销售额4,300万美元 (2024年上半年: 6,100万美元)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.